Anusha Kalbasi

/in /by
Email: anusha.kalbasi@mednet.ucla.edu

Publications:

Kalbasi A, Siurala M, Su LL, Tariveranmoshabad M, Picton LK, Ravikumar P, Li P, Lin JX, Escuin-Ordinas H, Da T, Kremer SV, Sun AL, Castelli S, Agarwal S, Scholler J, Song D, Rommel PC, Radaelli E, Young RM, Leonard WJ, Ribas A, June CH, Garcia KC. Potentiating adoptive cell therapy using synthetic IL-9 receptors. Nature. 2022 07; 607(7918):360-365. view on PubMed

Chantharasamee J, Wong K, Potivongsajarn P, Qorbani A, Motamed N, Brackert S, Cohen J, Chmielowski B, Kalbasi A, Rao J, Nelson S, Singh A. Retrospective analysis of adjuvant treatment for localized, operable uterine leiomyosarcoma. Cancer Med. 2022 Aug; 11(15):2906-2912. view on PubMed

Campbell KM, Thaker M, Medina E, Kalbasi A, Singh A, Ribas A, Nowicki TS. Spatial profiling reveals association between WNT pathway activation and T-cell exclusion in acquired resistance of synovial sarcoma to NY-ESO-1 transgenic T-cell therapy. J Immunother Cancer. 2022 03; 10(3). view on PubMed

Weidhaas J, Marco N, Scheffler AW, Kalbasi A, Wilenius K, Rietdorf E, Gill J, Heilig M, Desler C, Chin RK, Kaprealian T, McCloskey S, Raldow A, Raja NP, Kesari S, Carrillo J, Drakaki A, Scholz M, Telesca D. Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy. J Immunother Cancer. 2022 02; 10(2). view on PubMed

Valle LF, Bernthal N, Eilber FC, Shabason JE, Bedi M, Kalbasi A. Evaluating Thresholds to Adopt Hypofractionated Preoperative Radiotherapy as Standard of Care in Sarcoma. Sarcoma. 2021; 2021:3735874. view on PubMed

Gao Y, Ghodrati V, Kalbasi A, Fu J, Ruan D, Cao M, Wang C, Eilber FC, Bernthal N, Bukata S, Dry SM, Nelson SD, Kamrava M, Lewis J, Low DA, Steinberg M, Hu P, Yang Y. Prediction of soft tissue sarcoma response to radiotherapy using longitudinal diffusion MRI and a deep neural network with generative adversarial network-based data augmentation. Med Phys. 2021 Jun; 48(6):3262-3372. view on PubMed

Reddy VK, Jain V, Venigalla S, Levin WP, Wilson RJ, Weber KL, Kalbasi A, Sebro RA, Shabason JE. Radiotherapy Remains Underused in the Treatment of Soft-Tissue Sarcomas: Disparities in Practice Patterns in the United States. J Natl Compr Canc Netw. 2021 02 08; 1-12. view on PubMed

Li J, Duran MA, Dhanota N, Chatila WK, Bettigole SE, Kwon J, Sriram RK, Humphries MP, Salto-Tellez M, James JA, Hanna MG, Melms JC, Vallabhaneni S, Litchfield K, Usaite I, Biswas D, Bareja R, Li HW, Martin ML, Dorsaint P, Cavallo JA, Li P, Pauli C, Gottesdiener L, DiPardo BJ, Hollmann TJ, Merghoub T, Wen HY, Reis-Filho JS, Riaz N, Su SM, Kalbasi A, Vasan N, Powell SN, Wolchok JD, Elemento O, Swanton C, Shoushtari AN, Parkes EE, Izar B, Bakhoum SF. Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. Cancer Discov. 2021 05; 11(5):1212-1227. view on PubMed

Gao Y, Yoon S, Savjani R, Pham J, Kalbasi A, Raldow A, Low DA, Hu P, Yang Y. Comparison and evaluation of distortion correction techniques on an MR-guided radiotherapy system. Med Phys. 2021 Feb; 48(2):691-702. view on PubMed

Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, Champhekar A, Medina E, Torrejon DY, Shin DS, Tran P, Kim YJ, Puig-Saus C, Campbell K, Vega-Crespo A, Quist M, Martignier C, Luke JJ, Wolchok JD, Johnson DB, Chmielowski B, Hodi FS, Bhatia S, Sharfman W, Urba WJ, Slingluff CL, Diab A, Haanen JBAG, Algarra SM, Pardoll DM, Anagnostou V, Topalian SL, Velculescu VE, Speiser DE, Kalbasi A, Ribas A. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell. 2021 Jan 11; 39(1):122. view on PubMed

Kalbasi A, Tariveranmoshabad M, Hakimi K, Kremer S, Campbell KM, Funes JM, Vega-Crespo A, Parisi G, Champekar A, Nguyen C, Torrejon D, Shin D, Zaretsky JM, Damoiseaux RD, Speiser DE, Lopez-Casas PP, Quintero M, Ribas A. Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma. Sci Transl Med. 2020 10 14; 12(565). view on PubMed

Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, Champhekar A, Medina E, Torrejon DY, Shin DS, Tran P, Kim YJ, Puig-Saus C, Campbell K, Vega-Crespo A, Quist M, Martignier C, Luke JJ, Wolchok JD, Johnson DB, Chmielowski B, Hodi FS, Bhatia S, Sharfman W, Urba WJ, Slingluff CL, Diab A, Haanen JBAG, Algarra SM, Pardoll DM, Anagnostou V, Topalian SL, Velculescu VE, Speiser DE, Kalbasi A, Ribas A. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell. 2020 10 12; 38(4):500-515.e3. view on PubMed

Gao Y, Kalbasi A, Hsu W, Ruan D, Fu J, Shao J, Cao M, Wang C, Eilber FC, Bernthal N, Bukata S, Dry SM, Nelson SD, Kamrava M, Lewis J, Low DA, Steinberg M, Hu P, Yang Y. Treatment effect prediction for sarcoma patients treated with preoperative radiotherapy using radiomics features from longitudinal diffusion-weighted MRIs. Phys Med Biol. 2020 08 27; 65(17):175006. view on PubMed

Graham DS, van Dams R, Jackson NJ, Onyshchenko M, Eckardt MA, DiPardo BJ, Nelson SD, Chmielowski B, Shabason JE, Singh AS, Eilber FC, Kalbasi A. Chemotherapy and Survival in Patients with Primary High-Grade Extremity and Trunk Soft Tissue Sarcoma. Cancers (Basel). 2020 Aug 24; 12(9). view on PubMed

Graham DS, Onyshchenko M, Eckardt MA, DiPardo BJ, Venigalla S, Nelson SD, Chmielowski B, Singh AS, Shabason JE, Eilber FC, Kalbasi A. Low Rates of Chemotherapy Use for Primary, High-Grade Soft Tissue Sarcoma: A National Cancer Database Analysis. J Natl Compr Canc Netw. 2020 08; 18(8):1055-1065. view on PubMed

Campbell KM, Steiner G, Wells DK, Ribas A, Kalbasi A. Prioritization of SARS-CoV-2 epitopes using a pan-HLA and global population inference approach. bioRxiv. 2020 Jun 29. view on PubMed

Qi XS, Chu FI, Zhang Z, Chin RK, Raldow A, Kishan AU, Lee P, Chang A, Kalbasi A, Kamrava M, Steinberg ML, Low DA. Clinical Development and Evaluation of Megavoltage Topogram for Fast Patient Alignment on Helical Tomotherapy. Adv Radiat Oncol. 2020 Nov-Dec; 5(6):1334-1341. view on PubMed

Torrejon DY, Abril-Rodriguez G, Champhekar AS, Tsoi J, Campbell KM, Kalbasi A, Parisi G, Zaretsky JM, Garcia-Diaz A, Puig-Saus C, Cheung-Lau G, Wohlwender T, Krystofinski P, Vega-Crespo A, Lee CM, Mascaro P, Grasso CS, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Ribas A. Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade. Cancer Discov. 2020 08; 10(8):1140-1157. view on PubMed

Schaefer IM, Hong K, Kalbasi A. How Technology Is Improving the Multidisciplinary Care of Sarcoma. Am Soc Clin Oncol Educ Book. 2020 May; 40:445-462. view on PubMed

Nesseler JP, Lee MH, Nguyen C, Kalbasi A, Sayre JW, Romero T, Nickers P, McBride WH, Schaue D. Tumor Size Matters-Understanding Concomitant Tumor Immunity in the Context of Hypofractionated Radiotherapy with Immunotherapy. Cancers (Basel). 2020 Mar 18; 12(3). view on PubMed

Kalbasi A, Kamrava M, Chu FI, Telesca D, Van Dams R, Yang Y, Ruan D, Nelson SD, Dry SM, Hernandez J, Chmielowski B, Singh AS, Bukata SV, Bernthal NM, Steinberg ML, Weidhaas JB, Eilber FC. A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma. Clin Cancer Res. 2020 04 15; 26(8):1829-1836. view on PubMed

Abril-Rodriguez G, Torrejon DY, Liu W, Zaretsky JM, Nowicki TS, Tsoi J, Puig-Saus C, Baselga-Carretero I, Medina E, Quist MJ, Garcia AJ, Senapedis W, Baloglu E, Kalbasi A, Cheung-Lau G, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Wang CY, Grasso CS, Ribas A. Publisher Correction: PAK4 inhibition improves PD-1 blockade immunotherapy. Nat Cancer. 2020 02; 1(2):264. view on PubMed

Abril-Rodriguez G, Torrejon DY, Liu W, Zaretsky JM, Nowicki TS, Tsoi J, Puig-Saus C, Baselga-Carretero I, Medina E, Quist MJ, Garcia AJ, Senapedis W, Baloglu E, Kalbasi A, Cheung-Lau G, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Wang CY, Grasso CS, Ribas A. PAK4 inhibition improves PD-1 blockade immunotherapy. Nat Cancer. 2020; 1(1):46-58. view on PubMed

Graham DS, Russell TA, Eckardt MA, Motamedi K, Seeger LL, Singh AS, Bernthal NM, Kalbasi A, Dry SM, Nelson SD, Elashoff D, Levine BD, Eilber FC. Oncologic Accuracy of Image-guided Percutaneous Core-Needle Biopsy of Peripheral Nerve Sheath Tumors at a High-volume Sarcoma Center. Am J Clin Oncol. 2019 10; 42(10):739-743. view on PubMed

Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2020 01; 20(1):25-39. view on PubMed

Rice SR, Saboury B, Houshmand S, Salavati A, Kalbasi A, Goodman CR, Werner TJ, Vujaskovic Z, Simone CB, Alavi A. Quantification of global lung inflammation using volumetric 18F-FDG PET/CT parameters in locally advanced non-small-cell lung cancer patients treated with concurrent chemoradiotherapy: a comparison of photon and proton radiation therapy. Nucl Med Commun. 2019 Jun; 40(6):618-625. view on PubMed

Shurell-Linehan E, DiPardo BJ, Elliott IA, Graham DS, Eckardt MA, Dry SM, Nelson SD, Singh AS, Kalbasi A, Federman N, Bernthal NM, Eilber FC. Pathologic Response to Neoadjuvant Therapy is Associated With Improved Long-term Survival in High-risk Primary Localized Malignant Peripheral Nerve Sheath Tumors. Am J Clin Oncol. 2019 05; 42(5):426-431. view on PubMed

Paz H, Tsoi J, Kalbasi A, Grasso CS, McBride WH, Schaue D, Butterfield LH, Maurer DM, Ribas A, Graeber TG, Economou JS. Interleukin 32 expression in human melanoma. J Transl Med. 2019 04 05; 17(1):113. view on PubMed

Nowicki TS, Berent-Maoz B, Cheung-Lau G, Huang RR, Wang X, Tsoi J, Kaplan-Lefko P, Cabrera P, Tran J, Pang J, Macabali M, Garcilazo IP, Carretero IB, Kalbasi A, Cochran AJ, Grasso CS, Hu-Lieskovan S, Chmielowski B, Comin-Anduix B, Singh A, Ribas A. A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab. Clin Cancer Res. 2019 04 01; 25(7):2096-2108. view on PubMed

Pennington JD, Eilber FC, Eilber FR, Singh AS, Reed JP, Chmielowski B, Eckardt JJ, Bukata SV, Bernthal NM, Federman N, Nelson SD, Dry SM, Wang PC, Luu M, Selch MT, Steinberg ML, Kalbasi A, Kamrava M. Long-term Outcomes With Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue Sarcomas. Am J Clin Oncol. 2018 12; 41(12):1154-1161. view on PubMed

Ribas A, Medina T, Kummar S, Amin A, Kalbasi A, Drabick JJ, Barve M, Daniels GA, Wong DJ, Schmidt EV, Candia AF, Coffman RL, Leung ACF, Janssen RS. SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study. Cancer Discov. 2018 10; 8(10):1250-1257. view on PubMed

Kalbasi A, Ribas A. Antigen Presentation Keeps Trending in Immunotherapy Resistance. Clin Cancer Res. 2018 07 15; 24(14):3239-3241. view on PubMed

Kalbasi A, Kirk M, Teo BK, Diffenderfer E, Ding X, McDonough J, Murphy E, Hill-Kayser C. Proton craniospinal irradiation during the third trimester of pregnancy. Pract Radiat Oncol. 2018 May - Jun; 8(3):213-216. view on PubMed

Russell TA, Eckardt MA, Murakami T, Elliott IA, Kawaguchi K, Kiyuna T, Igarashi K, Li Y, Crompton JG, Graham DS, Dry SM, Bernthal N, Yanagawa J, Kalbasi A, Federman N, Chmielowski B, Singh AS, Hoffman RM, Eilber FC. Clinical Factors That Affect the Establishment of Soft Tissue Sarcoma Patient-Derived Orthotopic Xenografts: A University of California, Los Angeles, Sarcoma Program Prospective Clinical Trial. JCO Precis Oncol. 2017; 2017. view on PubMed

Kalbasi A, Rengan R. Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma. Transl Lung Cancer Res. 2017 Apr; 6(2):169-177. view on PubMed

Liu M, Kalbasi A, Beatty GL. Functio Laesa: Cancer Inflammation and Therapeutic Resistance. J Oncol Pract. 2017 03; 13(3):173-180. view on PubMed

Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, Palaskas N, Rodriguez GA, Parisi G, Azhdam A, Chmielowski B, Cherry G, Seja E, Berent-Maoz B, Shintaku IP, Le DT, Pardoll DM, Diaz LA, Tumeh PC, Graeber TG, Lo RS, Comin-Anduix B, Ribas A. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discov. 2017 02; 7(2):188-201. view on PubMed

Kalbasi A, Beatty GL, Berman AT. Expanding Tumor Lymphocytic Infiltration as a Prognostic Tool to Patients with NSCLC Who Are Treated with Radiotherapy? J Thorac Oncol. 2016 11; 11(11):e141-e142. view on PubMed

Kalbasi A, Komar C, Tooker GM, Liu M, Lee JW, Gladney WL, Ben-Josef E, Beatty GL. Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2017 Jan 01; 23(1):137-148. view on PubMed

Simone CB, Houshmand S, Kalbasi A, Salavati A, Alavi A. PET-Based Thoracic Radiation Oncology. PET Clin. 2016 Jul; 11(3):319-32. view on PubMed

Fernandes RS, Mota LG, Kalbasi A, Moghbel M, Werner TJ, Alavi A, Rubello D, Cardoso VN, de Barros AL. 99mTc-phytate as a diagnostic probe for assessing inflammatory reaction in malignant tumors. Nucl Med Commun. 2015 Oct; 36(10):1042-8. view on PubMed

Kalbasi A, Li J, Berman A, Swisher-McClure S, Smaldone M, Uzzo RG, Small DS, Mitra N, Bekelman JE. Dose-Escalated Irradiation and Overall Survival in Men With Nonmetastatic Prostate Cancer. JAMA Oncol. 2015 Oct; 1(7):897-906. view on PubMed

Kalbasi A, Swisher-McClure S, Mitra N, Sunderland R, Smaldone MC, Uzzo RG, Bekelman JE. Low rates of adjuvant radiation in patients with nonmetastatic prostate cancer with high-risk pathologic features. Cancer. 2014 Oct 01; 120(19):3089-96. view on PubMed

Kalbasi A, June CH, Haas N, Vapiwala N. Radiation and immunotherapy: a synergistic combination. J Clin Invest. 2013 Jul; 123(7):2756-63. view on PubMed

Xie C, Kim HJ, Haw JG, Kalbasi A, Gardner BK, Li G, Rao J, Chia D, Liong M, Punzalan RR, Marks LS, Pantuck AJ, de la Taille A, Wang G, Mukouyama H, Zeng G. A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases. J Transl Med. 2011 Apr 19; 9:43. view on PubMed

Kalbasi A, Fonsatti E, Natali PG, Altomonte M, Bertocci E, Cutaia O, Calabrò L, Chiou M, Tap W, Chmielowski B, Maio M, Ribas A. CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893. J Immunother. 2010 Oct; 33(8):810-6. view on PubMed

Kalbasi A, Shrimali RK, Chinnasamy D, Rosenberg SA. Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein. J Immunother. 2010 Sep; 33(7):672-83. view on PubMed